NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $9.85 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$9.84 -0.01 (-0.10%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lyell Immunopharma Stock (NASDAQ:LYEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyell Immunopharma alerts:Sign Up Key Stats Today's Range$9.81▼$10.1650-Day Range$9.85▼$15.7952-Week Range$9.81▼$45.00Volume108,899 shsAverage Volume126,705 shsMarket Capitalization$241.33 millionP/E RatioN/ADividend YieldN/APrice Target$40.86Consensus RatingModerate Buy Company Overview Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company’s research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors. Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates. Its pipeline has included investigational therapies targeting ROR1, a protein expressed by certain blood cancers and solid tumors, with programs such as LYL797 and LYL119. These candidates are being evaluated in clinical studies, and their safety and effectiveness have not been established. Founded in 2018, Lyell Immunopharma is headquartered in South San Francisco, California, and conducts research and clinical development activities primarily in the United States. The company became publicly traded on the Nasdaq under the symbol LYEL in 2021. Its work is focused on advancing engineered T-cell treatments rather than marketing approved products, and its programs remain subject to regulatory review and clinical-trial outcomes.AI Generated. May Contain Errors. Read More Lyell Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreLYEL MarketRank™: Lyell Immunopharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 499th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLyell Immunopharma has a consensus price target of $40.86, representing about 314.8% upside from its current price of $9.85.Amount of Analyst CoverageLyell Immunopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lyell Immunopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($7.20) to ($7.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyell Immunopharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.17% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 12.08, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently increased by 4.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.36 News SentimentLyell Immunopharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lyell Immunopharma this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,410.00 in company stock.Percentage Held by Insiders6.20% of the stock of Lyell Immunopharma is held by insiders.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYEL Stock News HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)September 26 at 10:08 AM | theglobeandmail.comLyell Immunopharma (NASDAQ:LYEL) Upgraded to "Hold" at Wall Street ZenSeptember 26 at 1:31 AM | americanbankingnews.comMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by robots but by America's oil and gas infrastructure. It's called the Patriot Income Plan, or P.I.P., and it pays 10% a year across 42 separate distribution dates. This year it's on track to pay out a record 53 billion dollars. Think of it as a personal stake in the world's largest energy producer, structured to deliver income on a regular schedule. | Freedom Financial (Ad)Financial Survey: Anika Therapeutics (NASDAQ:ANIK) versus Lyell Immunopharma (NASDAQ:LYEL)September 21, 2026 | americanbankingnews.comLyell Immunopharma To Participate in the Baird 2026 Global Healthcare ConferenceSeptember 14, 2026 | globenewswire.comLyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal CancerSeptember 10, 2026 | globenewswire.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026August 7, 2026 | finance.yahoo.comLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 25, 2026 | globenewswire.comSee More Headlines LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $30.78 at the start of the year. Since then, LYEL stock has decreased by 68.0% and is now trading at $9.85. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its earnings results on Thursday, August, 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts' consensus estimates of ($1.94) by $0.02. The firm earned $0 million during the quarter, compared to the consensus estimate of $0 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative trailing twelve-month return on equity of 91.62%. When did Lyell Immunopharma's stock split? Lyell Immunopharma's stock reverse split on Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an IPO on Tuesday, June 15th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Top institutional shareholders of Lyell Immunopharma include Opaleye Management Inc. (1.40%), venBio Partners LLC (1.38%), Velan Capital Investment Management LP (0.43%) and Squarepoint Ops LLC (0.17%). Insiders that own company stock include Lynn Seely, Lynn Seely, Richard Klausner, Richard Klausner, David Shook, Stephen J Hill, Gary K Lee, Veronica Sanchez Bulis, Sumant Ramachandra, Charles W Newton, Charles W Newton, Otis W Brawley and Otis W Brawley. View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyell Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/06/2026Today9/27/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LYEL's financial health is in the Yellow zone, according to TradeSmith. LYEL has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LYEL CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees161Year Founded2018Price Target and Rating Average Price Target for Lyell Immunopharma$40.86 High Price Target$49.00 Low Price Target$34.00 Potential Upside/Downside+314.8%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($12.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$274.45 million Net Margins-920,285.25% Pretax Margin-920,285.19% Return on Equity-91.62% Return on Assets-70.50% Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$40 thousand Price / Sales6,033.13 Cash FlowN/A Price / Cash FlowN/A Book Value$11.68 per share Price / Book0.84Miscellaneous Outstanding Shares24,500,000Free Float22,985,000Market Cap$241.33 million OptionableOptionable Beta-0.04 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:LYEL) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our Partners"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredIgnore oil - This is the Energy Story of the century…A drilling crew in Utah punched through three miles of granite in 16 days, a job the Department of Energy said...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
